Clinical Trial

IC-8 Apthera IOL New Enrollment Post Approval Study

Name: IC-8 Apthera IOL New Enrollment Post Approval Study — clinical trial record (NCT06060041)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.

Protocol Amendment History 8 amendments

This ClinicalTrials.gov record has been amended 8 times since 2023-09-23; most recent amendment 2026-01-09.

Trial Details

NCT Number	NCT06060041
Lead Sponsor	Bausch & Lomb Incorporated
Conditions	Cataract, Presbyopia, Posterior Capsule Opacification
Enrollment	435 participants
Start Date	2023-09-08
Primary Completion	2027-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-01-12